These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15710740)

  • 21. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
    ; Yusuf S; Pais P; Afzal R; Xavier D; Teo K; Eikelboom J; Sigamani A; Mohan V; Gupta R; Thomas N
    Lancet; 2009 Apr; 373(9672):1341-51. PubMed ID: 19339045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of heart failure.
    Horwich TB; Fonarow GC
    Curr Cardiol Rep; 2002 May; 4(3):194-9. PubMed ID: 11960587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease.
    Lauten WB; Khan QA; Rajagopalan S; Lerakis S; Rahman ST; Parthasarathy S; Khan BV
    Am J Cardiol; 2003 May; 91(9):1116-9. PubMed ID: 12714159
    [No Abstract]   [Full Text] [Related]  

  • 24. Key developments in cardiovascular medicine.
    Appleby MA; Hall A
    Practitioner; 2002 Jun; 246(1635):375-7, 380-2. PubMed ID: 12073696
    [No Abstract]   [Full Text] [Related]  

  • 25. [Secondary prevention in chronic coronary heart disease].
    Hunziker P; Bertel O
    Schweiz Med Wochenschr; 1997 Feb; 127(7):254-60. PubMed ID: 9157530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonlipid primary and secondary prevention strategies for coronary heart disease.
    Maron DJ
    Clin Cardiol; 1996 May; 19(5):419-23. PubMed ID: 8723603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention?
    Fox DJ; Kibiro M; Eichhöfer J; Curzen NP
    Postgrad Med J; 2005 Jun; 81(956):401-3. PubMed ID: 15937208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Receipt of cardiac medications upon discharge among men and women with acute coronary syndrome and nonobstructive coronary artery disease.
    Ramanath VS; Armstrong DF; Grzybowski M; Rahnama-Mohagdam S; Tamhane UU; Gordon K; Froehlich JB; Eagle KA; Jackson EA
    Clin Cardiol; 2010 Jan; 33(1):36-41. PubMed ID: 20063300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in the secondary prevention of coronary heart disease.
    Veverka A; Jolly JL
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):877-89. PubMed ID: 15500433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving patient outcomes in heart failure: evidence and barriers.
    Cleland JG
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i8-10:discussion i50. PubMed ID: 10956311
    [No Abstract]   [Full Text] [Related]  

  • 31. [Management of stable coronary artery disease].
    Jacobshagen C; Hasenfuss G
    MMW Fortschr Med; 2009 Nov; 151(47):45-9; quiz 50. PubMed ID: 20037979
    [No Abstract]   [Full Text] [Related]  

  • 32. Heart-protective drugs: a primer. Back to basics on how they work, side effects, interactions.
    Heart Advis; 2004 Dec; 7(12):3. PubMed ID: 15779133
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
    Yusuf S; Islam S; Chow CK; Rangarajan S; Dagenais G; Diaz R; Gupta R; Kelishadi R; Iqbal R; Avezum A; Kruger A; Kutty R; Lanas F; Lisheng L; Wei L; Lopez-Jaramillo P; Oguz A; Rahman O; Swidan H; Yusoff K; Zatonski W; Rosengren A; Teo KK;
    Lancet; 2011 Oct; 378(9798):1231-43. PubMed ID: 21872920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary prevention in coronary heart disease: baseline survey of provision in general practice.
    Campbell NC; Thain J; Deans HG; Ritchie LD; Rawles JM
    BMJ; 1998 May; 316(7142):1430-4. PubMed ID: 9572757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secondary prevention of coronary heart disease in elderly population of Turkey: A subgroup analysis of ELDERTURK study.
    Kilic S; Sümerkan MÇ; Emren V; Bekar L; Cersit S; Tunc E; Gök G; Altuntas E; Canpolat U; Sinan UY; Özmen N; Zoghi M
    Cardiol J; 2019; 26(1):13-19. PubMed ID: 28980279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ALLHAT study: results and clinical implications.
    Chrysant SG
    QJM; 2003 Oct; 96(10):771-3. PubMed ID: 14500864
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment protocol for secondary prevention in patients with coronary heart disease].
    Rubinstein A
    Harefuah; 1998 Feb; 134(4):319-20. PubMed ID: 10909517
    [No Abstract]   [Full Text] [Related]  

  • 38. ABCs of secondary prevention of CHD: easier said than done.
    Cohen JD
    Lancet; 2001 Mar; 357(9261):972-3. PubMed ID: 11293635
    [No Abstract]   [Full Text] [Related]  

  • 39. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
    Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
    QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Status of secondary prevention in patients undergoing coronary revascularization.
    Allen JK; Blumenthal RS; Margolis S; Young DR
    Am J Cardiol; 2001 May; 87(10):1203-6: A7. PubMed ID: 11356400
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.